Inhibikase Therapeutics I... (IKT)

2.40

0.10 (4.35%)

At close: Mar 03, 2025, 12:22 PM

Inhibikase Therapeutics Cash Flow Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Net Income	-19.03M	-18.05M	-14.79M	-2.85M	-5.72M	-2.15M	-436.07K	-628.74K
Depreciation & Amortization	177.4K	6.72K	n/a	n/a	n/a	n/a	n/a	n/a
Stock-Based Compensation	500.15K	458.15K	1.53M	573.7K	1.44M	642.23K	300.66K	310.09K
Other Working Capital	699.28K	39.53K	-2.33M	-217.57K	1.17M	256.73K	159.41K	98.91K
Other Non-Cash Items	31.54K	67K	721.63K	1.61M	2.32M	709.27K	534.62K	95.71K
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	234.76K	171.18K	-1.76M	-464.64K	1.63M	1.52M	-32.76K	193.36K
Operating Cash Flow	-18.09M	-17.35M	-14.3M	-1.13M	-338.29K	714.99K	-126.39K	-29.57K
Capital Expenditures	-14.24K	-243.25K	n/a	n/a	n/a	n/a	n/a	n/a
Acquisitions	n/a	243.25K	n/a	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	-29.43M	-20.73M	n/a	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	41.1M	4.96M	n/a	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	n/a	-243.25K	n/a	n/a	n/a	87.1K	n/a	n/a
Investing Cash Flow	11.66M	-16.01M	n/a	n/a	n/a	87.1K	n/a	n/a
Debt Repayment	n/a	-248.91K	-42.53K	272.8K	-22.81K	-26.31K	n/a	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	-138.56K	n/a	848.00	n/a	n/a	-1.59M	131.02K	-23.77K
Financial Cash Flow	8.41M	-204.77K	41.09M	15.06M	-22.81K	-439.19K	131.02K	-23.77K
Net Cash Flow	1.98M	-33.56M	26.8M	13.94M	-361.1K	362.89K	4.63K	-53.34K
Free Cash Flow	-18.1M	-17.59M	-14.3M	-1.13M	-338.29K	714.99K	-126.39K	-29.57K